[{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"Blacksmith Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Forge Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forge Therapeutics, Inc \/ Forge Therapeutics, Inc","highestDevelopmentStatusID":"3","companyTruncated":"Forge Therapeutics, Inc \/ Forge Therapeutics, Inc"},{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Forge Therapeutics, Inc","amount2":0.19,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Forge Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Forge Therapeutics, Inc \/ F. Hoffmann-La Roche"}]

Find Clinical Drug Pipeline Developments & Deals by Forge Therapeutics, Inc

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The Blacksmith metalloenzyme platform, a focused library of metal-binding pharmacophores with proprietary computational modeling, approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzyme's acti...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 02, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : Blacksmith Medicines

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Under this agreement, Roche has an exclusive option to license one of Forge’s antibiotic programmes. Forge will retain control of the programme prior to Roche exercising its option.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 25, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : $190.5 million

                          Deal Type : Collaboration

                          blank